This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Pimobendan
Accession Number
DB11450
Type
Small Molecule
Groups
Vet approved
Description
Not Available
Structure
Thumb
Synonyms
  • dl-Pimobendan
  • Pimobendan
  • Pimobendane
  • Pimobendanum
International/Other Brands
Acardi
Categories
UNII
34AP3BBP9T
CAS number
74150-27-9
Weight
Average: 334.379
Monoisotopic: 334.142975836
Chemical Formula
C19H18N4O2
InChI Key
GLBJJMFZWDBELO-UHFFFAOYSA-N
InChI
InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
IUPAC Name
6-[2-(4-methoxyphenyl)-1H-1,3-benzodiazol-5-yl]-5-methyl-4,5-dihydropyridazin-3-ol
SMILES
COC1=CC=C(C=C1)C1=NC2=C(N1)C=CC(=C2)C1=NN=C(O)CC1C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
  1. Galatulas I, Bossa R, Efstathiu G, Ninci MA: Esorubicin cardiotoxicity in vitro: antagonism by pimobendan. Acta Physiol Hung. 1990;75 Suppl:123-4. [PubMed:2371838]
  2. Hanzlicek AS, Gehring R, Kukanich B, Kukanich KS, Borgarelli M, Smee N, Olson EE, Margiocco M: Pharmacokinetics of oral pimobendan in healthy cats. J Vet Cardiol. 2012 Dec;14(4):489-96. doi: 10.1016/j.jvc.2012.06.002. Epub 2012 Oct 30. [PubMed:23116650]
  3. Fujino K, Sperelakis N, Solaro RJ: Direct effects of pimobendan on cardiac myofilaments. Prog Clin Biol Res. 1989;315:602-3. [PubMed:2798516]
  4. Peters P, Saborowski F, Kothe A: [Effect of pimobendan on peripheral hemodynamics]. Z Kardiol. 1989 Aug;78(8):538-44. [PubMed:2678794]
  5. van Meel JC, Mauz AB, Wienen W, Diederen W: Pimobendan increases survival of cardiomyopathic hamsters. J Cardiovasc Pharmacol. 1989 Mar;13(3):508-9. [PubMed:2471899]
  6. Zvirgzdins A, Delina M, Mishnev A, Actins A: Pimobendan B from powder diffraction data. Acta Crystallogr Sect E Struct Rep Online. 2013 Oct 19;69(Pt 11):o1677. doi: 10.1107/S1600536813028353. eCollection 2013 Nov 1. [PubMed:24526935]
  7. van Meel JC, Diederen W: Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol. 1989;14 Suppl 2:S1-6. [PubMed:2478784]
  8. Tsuda T, Izumi T, Kodama M, Hanawa H, Takahashi M, Suzuki M, Aizaki T, Uchiyama H, Kuwano H, Shibata A: Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan. Jpn Heart J. 1992 Mar;33(2):193-203. [PubMed:1593749]
  9. Scheld HH, Fritsche R, Schlepper M, van Meel JC: Pimobendan increases calcium sensitivity of skinned human papillary muscle fibers. J Clin Pharmacol. 1989 Apr;29(4):360-6. [PubMed:2723124]
External Links
KEGG Drug
D01133
ChemSpider
4657
BindingDB
50282617
ChEBI
32003
ChEMBL
CHEMBL24646
Wikipedia
Pimobendan

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
PowderNot applicable1 g/1g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0113 mg/mLALOGPS
logP3.5ALOGPS
logP2.68ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)5.23ChemAxon
pKa (Strongest Basic)4.51ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area82.86 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity105.2 m3·mol-1ChemAxon
Polarizability37.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0129000000-900366a58e4d7b7da367

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbenzimidazoles. These are compounds containing a phenylbenzimidazole skeleton, which consists of a benzimidazole moiety where its imidazole ring is attached to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Phenylbenzimidazoles
Direct Parent
Phenylbenzimidazoles
Alternative Parents
Phenylimidazoles / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / Pyridazines and derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 1 more
Substituents
Phenylbenzimidazole / 2-phenylimidazole / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Monocyclic benzene moiety / Benzenoid / Pyridazine
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyridazinone, benzimidazoles (CHEBI:32003)

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Curator comments
Data supporting this enzyme action are limited to an in vitro study.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Kuriya Si, Ohmori S, Hino M, Ishii I, Nakamura H, Senda C, Igarashi T, Kiuchi M, Kitada M: Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes. Drug Metab Dispos. 2000 Jan;28(1):73-8. [PubMed:10611143]

Drug created on February 25, 2016 11:51 / Updated on September 02, 2019 19:24